fenofibrate has been researched along with Innate Inflammatory Response in 79 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA), with those of fenofibrate, on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects." | 9.16 | Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects. ( Bragt, MC; Mensink, RP, 2012) |
| "Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients." | 9.15 | Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, Y; Lee, YH; Lim, S; Quon, MJ; Sakuma, I; Shin, EK, 2011) |
| "To compare lipid lowering profile and effects on markers of inflammation of rosuvastatin and fenofibrate in patients with type 2 diabetes with low high density lipoprotein (HDL) cholesterol (CH)." | 9.14 | [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation]. ( Gratsianskiĭ, NA; Iavelov, IS; Masenko, VP; Polenova, NV; Vaulin, NA, 2009) |
| "We prospectively compared the anti-inflammatory and antidyslipidemic effects of fenofibrate and statins in rheumatoid arthritis (RA) patients." | 9.14 | A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. ( Goto, M, 2010) |
| " The objective of this 2-group parallel study was to investigate the differential effects of a 6-week treatment with either atorvastatin 20 mg/d alone (n = 19) or micronized fenofibrate 200 mg/d alone (n = 19) on inflammation, cell adhesion, and oxidation markers in type 2 diabetes mellitus subjects with marked hypertriglyceridemia." | 9.13 | Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. ( Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "This was a prospective, randomized, placebo-controlled trial involving the group of 91 ambulatory patients with impaired glucose tolerance (IGT) (diagnosed on the basis of the American Diabetes Association criteria), randomly divided into three groups, simultaneously treated for 30 d with the AHA step 1 diet (n = 30), micronized fenofibrate (267 mg/d, n = 31), or placebo (n = 30)." | 9.12 | Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. ( Herman, ZS; Krysiak, R; Okopień, B, 2006) |
| "The aim of the study was to determine whether a short-term treatment with simvastatin or fenofibrate may result in beneficial anti-inflammatory and antithrombotic effects in patients with high risk of coronary artery disease." | 9.11 | Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. ( Celinska-Löwenhoff, M; Domagala, TB; Dropinski, J; Iwaniec, T; Löwenhoff, T; Szczeklik, A; Undas, A, 2005) |
| "We investigated the effects of fenofibrate, peroxisome proliferator-activated receptors (PPARs) agonist, on endothelial function in patients with hypertriglyceridemia." | 9.11 | Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. ( Cheon Lee, K; Hwan Han, S; Kon Koh, K; Kyu Jin, D; Kyun Shin, E; Sakuma, I; Sik Kim, H; Yeal Ahn, J, 2004) |
| "These results suggest that fenofibrate treatment attenuates insulin resistance in part by reducing tissue inflammation and TNFα expression in HFD-fed OVX mice." | 8.31 | Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice. ( Jeon, S; Lee, J; Lee, M; Yoon, M, 2023) |
| "Fenofibrate potently attenuated LG inflammation in a model of autoimmune dry eye, and this effect might partially result from regulating Th1/Th17/Treg cell responses by activating PPAR-α/LXR-β signaling." | 8.12 | PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome-Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice. ( Dang, W; Guo, X; Li, N; Nian, H; Sun, D; Wang, Y; Wei, R, 2022) |
| " Valproic acid (VPA) is an anticonvulsant drug in both human and rodents with teratogenic effects during pregnancy." | 7.91 | Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. ( Mirza, R; Sharma, B, 2019) |
| "Fenofibrate (FF) is commonly used clinically as a lipid-lowering drug, but whether it participates in endoplasmic reticulum (ER) stress and decreases inflammation in skeletal muscle is still unknown." | 7.83 | Fenofibrate improves high-fat diet-induced and palmitate-induced endoplasmic reticulum stress and inflammation in skeletal muscle. ( Bao, YY; Chen, GJ; Chen, L; Dai, F; Jiang, T; Lu, YX; Zhang, Q, 2016) |
| "The aim of this study was to investigate the possible beneficial effects of Fenofibrate on renal ischemia-reperfusion injury (IRI) in mice and its potential mechanism." | 7.81 | Fenofibrate pre-treatment suppressed inflammation by activating phosphoinositide 3 kinase/protein kinase B (PI3K/Akt) signaling in renal ischemia-reperfusion injury. ( He, YH; Yang, FJ; Zhou, JH, 2015) |
| "The objectives of this study were to determine the effect of osthole on the insulin resistance (IR) in high-fat and high-sucrose-induced fatty liver rats and to investigate its potential mechanisms." | 7.77 | Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. ( Qi, Z; Wang, H; Xie, M; Xue, J; Zhang, Y, 2011) |
| " In the present study, we sought to investigate in greater detail the effect of fenofibrate and its mechanism of action on renal inflammation and tubulointerstitial fibrosis in an animal model of type 2 diabetes mellitus." | 7.76 | Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. ( Emmett, N; Li, L; Mann, D; Zhao, X, 2010) |
| "Fenofibrate reduces atherosclerosis more than can be explained by lowering total plasma cholesterol per se." | 7.73 | Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. ( de Vries-van der Weij, J; Kleemann, R; Koenig, W; Kooistra, T; Princen, HM; Toet, K; Verschuren, L, 2006) |
| "The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats." | 7.72 | PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. ( Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL, 2004) |
| "Fenofibrate was shown to increase serum sirtuin 1 and decrease serum fetuin A levels in obese patients." | 6.80 | Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. ( Abd El-Razek, RS; El-Hefnawy, MH; El-Mesallamy, HO; Noureldein, MH, 2015) |
| "Treatment with fenofibrate resulted in significant decrease in CRP and IL-6 concentrations and improvement in lipid profile." | 6.78 | The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study. ( Kalinovskaya, N; Polovnikova, O; Shirinsky, I; Shirinsky, V, 2013) |
| "Niacin was more effective at lowering LDL-C, Lp (a), and hs-CRP." | 6.75 | Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. ( Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J, 2010) |
| "We have developed a co-assembled nanosystem based on fenofibrate and ketoprofen by tactfully utilizing their simultaneous benzophenone interaction, which greatly enhances the bioavailability of fenofibrate and plays a role in the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses." | 5.56 | Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD). ( Fan, G; Liu, J; Ma, C; Ren, C; Shang, Y; Wang, Z; Yang, C; Yang, L; Zhang, J, 2020) |
| "Fenofibrate was given to mice in rodent chow." | 5.48 | Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. ( Cheng, R; Li, J; Liu, Q; Ma, JX; Yi, J; Zhang, F; Zhang, X, 2018) |
| "Fenofibrate treatment restored to normal values the ejection and shortening fractions, left ventricular end-diastolic, left ventricular end-systolic diameter, and isovolumic relaxation time." | 5.46 | Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. ( Cevey, ÁC; Donato, M; Gelpi, RJ; Goren, NB; Mirkin, GA; Penas, FN; Rada, MJ, 2017) |
| "Cotreatment with fenofibrate blunts these processes." | 5.42 | Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis. ( Farris, RA; O'Brien, CE; Price, ET; Stolarz, AJ; Wiley, CA, 2015) |
| "Inflammation is implicated in chronic heart failure (CHF)." | 5.35 | Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. ( Chen, JW; Huang, WP; Jen, HL; Lin, SJ; Yin, WH; Young, MS, 2009) |
| "To compare the effects of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA), with those of fenofibrate, on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects." | 5.16 | Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects. ( Bragt, MC; Mensink, RP, 2012) |
| "Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients." | 5.15 | Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, Y; Lee, YH; Lim, S; Quon, MJ; Sakuma, I; Shin, EK, 2011) |
| "To compare lipid lowering profile and effects on markers of inflammation of rosuvastatin and fenofibrate in patients with type 2 diabetes with low high density lipoprotein (HDL) cholesterol (CH)." | 5.14 | [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation]. ( Gratsianskiĭ, NA; Iavelov, IS; Masenko, VP; Polenova, NV; Vaulin, NA, 2009) |
| "We prospectively compared the anti-inflammatory and antidyslipidemic effects of fenofibrate and statins in rheumatoid arthritis (RA) patients." | 5.14 | A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. ( Goto, M, 2010) |
| "Fenofibrate treatment was not associated with beneficial changes in IMT, augmentation index, or biomarkers of inflammation and endothelial function." | 5.13 | Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. ( Hiukka, A; Hulten, LM; Keech, AC; Leinonen, ES; Salonen, JT; Taskinen, MR; Tuomainen, TP; Watanabe, H; Westerbacka, J; Wiklund, O; Yki-Järvinen, H, 2008) |
| " The objective of this 2-group parallel study was to investigate the differential effects of a 6-week treatment with either atorvastatin 20 mg/d alone (n = 19) or micronized fenofibrate 200 mg/d alone (n = 19) on inflammation, cell adhesion, and oxidation markers in type 2 diabetes mellitus subjects with marked hypertriglyceridemia." | 5.13 | Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. ( Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "Patients (n = 300) with type II diabetes, mixed dyslipidemia (2 or more of low-density lipoprotein > or =100 mg/dl, triglycerides > or =200 mg/dl, or high-density lipoprotein <40 mg/dl), and no history of coronary heart disease were randomly assigned to receive simvastatin 20 mg, fenofibrate 160 mg, or a combination of simvastatin 20 mg and fenofibrate 160 mg daily." | 5.12 | The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. ( Anderson, JL; Horne, BD; Jensen, JR; Lanman, RB; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Wolfert, RL; Yannicelli, HD, 2006) |
| "This was a prospective, randomized, placebo-controlled trial involving the group of 91 ambulatory patients with impaired glucose tolerance (IGT) (diagnosed on the basis of the American Diabetes Association criteria), randomly divided into three groups, simultaneously treated for 30 d with the AHA step 1 diet (n = 30), micronized fenofibrate (267 mg/d, n = 31), or placebo (n = 30)." | 5.12 | Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. ( Herman, ZS; Krysiak, R; Okopień, B, 2006) |
| "The aim of the study was to determine whether a short-term treatment with simvastatin or fenofibrate may result in beneficial anti-inflammatory and antithrombotic effects in patients with high risk of coronary artery disease." | 5.11 | Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. ( Celinska-Löwenhoff, M; Domagala, TB; Dropinski, J; Iwaniec, T; Löwenhoff, T; Szczeklik, A; Undas, A, 2005) |
| "We investigated the effects of fenofibrate, peroxisome proliferator-activated receptors (PPARs) agonist, on endothelial function in patients with hypertriglyceridemia." | 5.11 | Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. ( Cheon Lee, K; Hwan Han, S; Kon Koh, K; Kyu Jin, D; Kyun Shin, E; Sakuma, I; Sik Kim, H; Yeal Ahn, J, 2004) |
| "These results suggest that fenofibrate treatment attenuates insulin resistance in part by reducing tissue inflammation and TNFα expression in HFD-fed OVX mice." | 4.31 | Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice. ( Jeon, S; Lee, J; Lee, M; Yoon, M, 2023) |
| "Fenofibrate potently attenuated LG inflammation in a model of autoimmune dry eye, and this effect might partially result from regulating Th1/Th17/Treg cell responses by activating PPAR-α/LXR-β signaling." | 4.12 | PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome-Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice. ( Dang, W; Guo, X; Li, N; Nian, H; Sun, D; Wang, Y; Wei, R, 2022) |
| " Valproic acid (VPA) is an anticonvulsant drug in both human and rodents with teratogenic effects during pregnancy." | 3.91 | Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. ( Mirza, R; Sharma, B, 2019) |
| "Fenofibrate attenuated cardiac hypertrophy, as evidenced by histological and MRI analyses, and protected the kidneys, preventing morphological alterations, changes in arterial blood flow velocity, and increases in 24-h proteinuria." | 3.88 | Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection. ( Abbate, M; Castiglioni, L; Crestani, M; Fiaschè, M; Fiordaliso, F; Foray, C; Gelosa, P; Giudici, M; Guerrini, U; Mitro, N; Pignieri, A; Rottoli, D; Sironi, L; Tremoli, E; Zoja, C, 2018) |
| "Fenofibrate (FF) is commonly used clinically as a lipid-lowering drug, but whether it participates in endoplasmic reticulum (ER) stress and decreases inflammation in skeletal muscle is still unknown." | 3.83 | Fenofibrate improves high-fat diet-induced and palmitate-induced endoplasmic reticulum stress and inflammation in skeletal muscle. ( Bao, YY; Chen, GJ; Chen, L; Dai, F; Jiang, T; Lu, YX; Zhang, Q, 2016) |
| "The aim of this study was to investigate the possible beneficial effects of Fenofibrate on renal ischemia-reperfusion injury (IRI) in mice and its potential mechanism." | 3.81 | Fenofibrate pre-treatment suppressed inflammation by activating phosphoinositide 3 kinase/protein kinase B (PI3K/Akt) signaling in renal ischemia-reperfusion injury. ( He, YH; Yang, FJ; Zhou, JH, 2015) |
| " This study aimed to evaluate the effect of fenofibrate and gemfibrozil on inflammation in macrophages and reveal pathways these agents may affect." | 3.81 | PPARα agonists inhibit inflammatory activation of macrophages through upregulation of β-defensin 1. ( Ann, SJ; Chung, JH; Jang, J; Kang, SM; Kim, SH; Lee, SH; Park, BH; Park, S, 2015) |
| " In this study, we examined molecular mechanisms that explain differential effects of a PPARα agonist (fenofibrate) and a PPARγ agonist (rosiglitazone) on macrophages during obesity-induced atherogenesis." | 3.79 | PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression. ( Arnould, T; Geeraert, B; Holvoet, P; Hulsmans, M; Tsatsanis, C, 2013) |
| "Biomarkers of inflammation were measured in participants of the Genetics of Lipid Lowering Drugs and Diet Network (n=1092) before and after a 3-week daily treatment with 160 mg of fenofibrate." | 3.78 | A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network. ( Arnett, DK; Aslibekyan, S; Borecki, IB; Hopkins, PN; Irvin, MR; Kabagambe, EK; Lai, CQ; Ordovas, JM; Shen, J; Straka, RJ; Tiwari, HK; Tsai, MY, 2012) |
| "The objectives of this study were to determine the effect of osthole on the insulin resistance (IR) in high-fat and high-sucrose-induced fatty liver rats and to investigate its potential mechanisms." | 3.77 | Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. ( Qi, Z; Wang, H; Xie, M; Xue, J; Zhang, Y, 2011) |
| " In the present study, we sought to investigate in greater detail the effect of fenofibrate and its mechanism of action on renal inflammation and tubulointerstitial fibrosis in an animal model of type 2 diabetes mellitus." | 3.76 | Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. ( Emmett, N; Li, L; Mann, D; Zhao, X, 2010) |
| "NO deficiency and activation of inflammation are involved in vascular impairment in rats with high-fat diet-induced hyperlipidemia, and fenofibrate can effectively prevent atherosclerosis by restoring NO concentration and down-regulating VCAM-1 expression in these rats." | 3.74 | [Impact of fenofibrate on NO and endothelial VCAM-1 expression in hyperlipidemic rats]. ( Guo, HS; He, ZC; Lin, JC; Ou, BR; Sun, M; Wu, J, 2007) |
| "Fenofibrate reduces atherosclerosis more than can be explained by lowering total plasma cholesterol per se." | 3.73 | Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. ( de Vries-van der Weij, J; Kleemann, R; Koenig, W; Kooistra, T; Princen, HM; Toet, K; Verschuren, L, 2006) |
| "The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats." | 3.72 | PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. ( Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL, 2004) |
| "Fenofibrate was shown to increase serum sirtuin 1 and decrease serum fetuin A levels in obese patients." | 2.80 | Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. ( Abd El-Razek, RS; El-Hefnawy, MH; El-Mesallamy, HO; Noureldein, MH, 2015) |
| "Treatment with fenofibrate resulted in significant decrease in CRP and IL-6 concentrations and improvement in lipid profile." | 2.78 | The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study. ( Kalinovskaya, N; Polovnikova, O; Shirinsky, I; Shirinsky, V, 2013) |
| "Niacin was more effective at lowering LDL-C, Lp (a), and hs-CRP." | 2.75 | Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. ( Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J, 2010) |
| "Obesity is a low grade inflammatory state associated with premature cardiovascular morbidity and mortality." | 2.73 | Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. ( McCance, DR; McMahon, R; Powell, L; Ryan, KE; Trimble, ER, 2007) |
| "Diabetic retinopathy was associated with ∼ 1." | 2.47 | Does microvascular disease predict macrovascular events in type 2 diabetes? ( Dodson, PM; Fioretto, P; Rosenson, RS, 2011) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease in developed countries, and its prevalence is increasing." | 2.44 | Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. ( Brown, WV, 2008) |
| "Then fenofibrate 25 mg/kg was orally administrated to mice twice/day for 14 days." | 1.62 | Fenofibrate reverses liver fibrosis in cholestatic mice induced by alpha-naphthylisothiocyanate. ( Dai, M; Li, S; Liu, A; Lu, Z; Luo, J; Luo, Y; Qiu, J; Yang, J; Zheng, X, 2021) |
| "We have developed a co-assembled nanosystem based on fenofibrate and ketoprofen by tactfully utilizing their simultaneous benzophenone interaction, which greatly enhances the bioavailability of fenofibrate and plays a role in the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses." | 1.56 | Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD). ( Fan, G; Liu, J; Ma, C; Ren, C; Shang, Y; Wang, Z; Yang, C; Yang, L; Zhang, J, 2020) |
| "Treatment with fenofibrate improved renal function by improving creatinine clearance (P = 0." | 1.48 | Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy. ( Mohammadi, MT; Rezaee, R; Sahebkar, A; Yaribeygi, H, 2018) |
| "Fenofibrate was given to mice in rodent chow." | 1.48 | Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. ( Cheng, R; Li, J; Liu, Q; Ma, JX; Yi, J; Zhang, F; Zhang, X, 2018) |
| "Fenofibrate treatment restored to normal values the ejection and shortening fractions, left ventricular end-diastolic, left ventricular end-systolic diameter, and isovolumic relaxation time." | 1.46 | Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. ( Cevey, ÁC; Donato, M; Gelpi, RJ; Goren, NB; Mirkin, GA; Penas, FN; Rada, MJ, 2017) |
| "Hugan Qingzhi tablets alleviates hyperlipidemia and inflammation in rats fed with high-fat diet possibly by activating AMPK pathway and suppress NF-αB activity to arrest the progression of nonalcoholic fatty liver disease." | 1.46 | [Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-κB-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease]. ( Tang, WJ; Xia, F; Yao, XR; Zhou, BJ, 2017) |
| "Cotreatment with fenofibrate blunts these processes." | 1.42 | Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis. ( Farris, RA; O'Brien, CE; Price, ET; Stolarz, AJ; Wiley, CA, 2015) |
| "The fenofibrate-treated group also showed a significantly higher level of hepatic SOD content (untreated model: 67." | 1.39 | [Anti-fibrosis effects of fenofibrate in mice with hepatic fibrosis]. ( Jiang, JJ; Li, L; Xie, C; Xu, YP; Zhu, YY, 2013) |
| "Inflammation is known to cause significant neuronal damage and axonal injury in many neurological disorders." | 1.37 | Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function. ( Ginty, M; Gray, E; Kemp, K; Scolding, N; Wilkins, A, 2011) |
| "Inflammation is implicated in chronic heart failure (CHF)." | 1.35 | Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. ( Chen, JW; Huang, WP; Jen, HL; Lin, SJ; Yin, WH; Young, MS, 2009) |
| "Fenofibrate treatment decreased hepatic macrophage accumulation and abolished steatosis." | 1.33 | Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. ( Buffat, L; Gijbels, MJ; Hofker, MH; Maeda, N; Noel, B; Shiri-Sverdlov, R; Staels, B; van Bilsen, M; van Gorp, PJ; Wouters, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.27) | 18.2507 |
| 2000's | 25 (31.65) | 29.6817 |
| 2010's | 41 (51.90) | 24.3611 |
| 2020's | 12 (15.19) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Xiang, J | 1 |
| Lu, M | 1 |
| Shi, M | 1 |
| Cheng, X | 1 |
| Kwakwa, KA | 1 |
| Davis, JL | 1 |
| Su, X | 1 |
| Bakewell, SJ | 1 |
| Zhang, Y | 4 |
| Fontana, F | 1 |
| Xu, Y | 2 |
| Veis, DJ | 1 |
| DiPersio, JF | 1 |
| Ratner, L | 1 |
| Sanderson, RD | 1 |
| Noseda, A | 1 |
| Mollah, S | 1 |
| Li, J | 2 |
| Weilbaecher, KN | 1 |
| Guo, X | 1 |
| Dang, W | 1 |
| Li, N | 1 |
| Wang, Y | 2 |
| Sun, D | 1 |
| Nian, H | 1 |
| Wei, R | 1 |
| Wang, X | 2 |
| Yu, C | 1 |
| Liu, X | 1 |
| Yang, J | 2 |
| Feng, Y | 1 |
| Wu, Y | 1 |
| Zhu, Y | 1 |
| Li, W | 1 |
| Alemán, MN | 1 |
| Sánchez, SS | 1 |
| Honoré, SM | 1 |
| Rigazio, CS | 3 |
| Mariz-Ponte, N | 3 |
| Pérez Caballero, E | 3 |
| Penas, FN | 4 |
| Goren, NB | 4 |
| Santamaría, MH | 3 |
| Corral, RS | 3 |
| Jin, L | 1 |
| Hua, H | 1 |
| Ji, Y | 1 |
| Jia, Z | 1 |
| Peng, M | 1 |
| Huang, S | 1 |
| Park, A | 1 |
| Heo, TH | 1 |
| Lee, J | 1 |
| Jeon, S | 1 |
| Lee, M | 1 |
| Yoon, M | 1 |
| Wang, Z | 1 |
| Ma, C | 1 |
| Shang, Y | 1 |
| Yang, L | 2 |
| Zhang, J | 4 |
| Yang, C | 1 |
| Ren, C | 1 |
| Liu, J | 2 |
| Fan, G | 1 |
| Jin, M | 1 |
| Zhu, T | 1 |
| Tocher, DR | 1 |
| Luo, J | 2 |
| Shen, Y | 1 |
| Li, X | 1 |
| Pan, T | 1 |
| Yuan, Y | 1 |
| Betancor, MB | 1 |
| Jiao, L | 1 |
| Sun, P | 1 |
| Zhou, Q | 1 |
| Heffernan, KS | 1 |
| Ranadive, SM | 1 |
| Jae, SY | 1 |
| Lu, Z | 1 |
| Li, S | 1 |
| Luo, Y | 1 |
| Dai, M | 1 |
| Zheng, X | 1 |
| Qiu, J | 1 |
| Liu, A | 1 |
| Yusuf, N | 1 |
| Hidalgo, B | 1 |
| Irvin, MR | 2 |
| Sha, J | 1 |
| Zhi, D | 1 |
| Tiwari, HK | 3 |
| Absher, D | 1 |
| Arnett, DK | 3 |
| Aslibekyan, SW | 1 |
| Zheng, S | 1 |
| Ren, X | 1 |
| Han, T | 1 |
| Chen, Y | 2 |
| Qiu, H | 1 |
| Liu, W | 1 |
| Hu, Y | 1 |
| Cevey, ÁC | 1 |
| Mirkin, GA | 1 |
| Donato, M | 1 |
| Rada, MJ | 1 |
| Gelpi, RJ | 1 |
| Liu, Q | 1 |
| Zhang, F | 1 |
| Zhang, X | 1 |
| Cheng, R | 1 |
| Ma, JX | 1 |
| Yi, J | 1 |
| Castiglioni, L | 2 |
| Pignieri, A | 2 |
| Fiaschè, M | 1 |
| Giudici, M | 1 |
| Crestani, M | 1 |
| Mitro, N | 1 |
| Abbate, M | 1 |
| Zoja, C | 1 |
| Rottoli, D | 1 |
| Foray, C | 1 |
| Fiordaliso, F | 1 |
| Guerrini, U | 1 |
| Tremoli, E | 2 |
| Sironi, L | 2 |
| Gelosa, P | 2 |
| Galhotra, P | 1 |
| Prabhakar, P | 1 |
| Meghwani, H | 1 |
| Mohammed, SA | 1 |
| Banerjee, SK | 1 |
| Seth, S | 1 |
| Hote, MP | 1 |
| Reeta, KH | 1 |
| Ray, R | 1 |
| Maulik, SK | 1 |
| Yaribeygi, H | 1 |
| Mohammadi, MT | 1 |
| Rezaee, R | 1 |
| Sahebkar, A | 1 |
| Mirza, R | 1 |
| Sharma, B | 1 |
| Millar, JS | 1 |
| Hulsmans, M | 1 |
| Geeraert, B | 1 |
| Arnould, T | 1 |
| Tsatsanis, C | 1 |
| Holvoet, P | 1 |
| Yang, CS | 1 |
| Yuk, JM | 1 |
| Kim, JJ | 1 |
| Hwang, JH | 1 |
| Lee, CH | 1 |
| Kim, JM | 1 |
| Oh, GT | 1 |
| Choi, HS | 1 |
| Jo, EK | 1 |
| Wang, W | 1 |
| Bai, L | 1 |
| Qiao, H | 1 |
| Lu, Y | 1 |
| Lin, R | 1 |
| Ren, F | 1 |
| Ji, M | 1 |
| Xie, C | 1 |
| Li, L | 2 |
| Xu, YP | 1 |
| Zhu, YY | 1 |
| Jiang, JJ | 1 |
| Xuan, AG | 1 |
| Long, DH | 1 |
| Zhang, M | 1 |
| Ji, WD | 1 |
| Zhang, WJ | 1 |
| Liu, JH | 1 |
| Hong, LP | 1 |
| He, XS | 1 |
| Chen, WL | 1 |
| Yang, FJ | 1 |
| He, YH | 1 |
| Zhou, JH | 1 |
| Ann, SJ | 1 |
| Chung, JH | 1 |
| Park, BH | 1 |
| Kim, SH | 1 |
| Jang, J | 1 |
| Park, S | 2 |
| Kang, SM | 2 |
| Lee, SH | 2 |
| Dubé, MP | 1 |
| Komarow, L | 1 |
| Fichtenbaum, CJ | 1 |
| Cadden, JJ | 1 |
| Overton, ET | 1 |
| Hodis, HN | 1 |
| Currier, JS | 1 |
| Stein, JH | 1 |
| Noureldein, MH | 1 |
| Abd El-Razek, RS | 1 |
| El-Hefnawy, MH | 1 |
| El-Mesallamy, HO | 1 |
| Cui, Y | 1 |
| Wang, XL | 1 |
| Shang, X | 1 |
| Qi, ZG | 1 |
| Xue, J | 2 |
| Zhao, X | 2 |
| Deng, M | 1 |
| Xie, ML | 1 |
| Stolarz, AJ | 1 |
| Farris, RA | 1 |
| Wiley, CA | 1 |
| O'Brien, CE | 1 |
| Price, ET | 1 |
| Esmaeili, MA | 1 |
| Yadav, S | 1 |
| Gupta, RK | 1 |
| Waggoner, GR | 1 |
| Deloach, A | 1 |
| Calingasan, NY | 1 |
| Beal, MF | 1 |
| Kiaei, M | 1 |
| Dai, F | 1 |
| Jiang, T | 1 |
| Bao, YY | 1 |
| Chen, GJ | 1 |
| Chen, L | 2 |
| Zhang, Q | 1 |
| Lu, YX | 1 |
| Zhao, Y | 1 |
| Yan, L | 1 |
| Luo, XM | 1 |
| Peng, L | 1 |
| Guo, H | 1 |
| Jing, Z | 1 |
| Yang, LC | 1 |
| Hu, R | 1 |
| Huang, XF | 1 |
| Wang, YQ | 1 |
| Jin, X | 1 |
| van der Krieken, SE | 1 |
| Popeijus, HE | 1 |
| Konings, M | 1 |
| Dullens, SP | 1 |
| Mensink, RP | 2 |
| Plat, J | 1 |
| Yao, XR | 1 |
| Xia, F | 1 |
| Tang, WJ | 1 |
| Zhou, BJ | 1 |
| Brown, WV | 1 |
| Hiukka, A | 1 |
| Westerbacka, J | 1 |
| Leinonen, ES | 1 |
| Watanabe, H | 1 |
| Wiklund, O | 1 |
| Hulten, LM | 1 |
| Salonen, JT | 1 |
| Tuomainen, TP | 1 |
| Yki-Järvinen, H | 1 |
| Keech, AC | 1 |
| Taskinen, MR | 1 |
| Polenova, NV | 1 |
| Vaulin, NA | 1 |
| Masenko, VP | 1 |
| Iavelov, IS | 1 |
| Gratsianskiĭ, NA | 1 |
| Huang, WP | 1 |
| Yin, WH | 1 |
| Chen, JW | 1 |
| Jen, HL | 1 |
| Young, MS | 1 |
| Lin, SJ | 1 |
| Ji, YY | 1 |
| Liu, JT | 1 |
| Liu, N | 1 |
| Wang, ZD | 1 |
| Liu, CH | 1 |
| Goto, M | 1 |
| Emmett, N | 1 |
| Mann, D | 1 |
| Banfi, C | 1 |
| Gianella, A | 1 |
| Brioschi, M | 1 |
| Nobili, E | 1 |
| Cimino, M | 1 |
| Qi, Z | 1 |
| Wang, H | 1 |
| Xie, M | 1 |
| Wi, J | 1 |
| Kim, JY | 1 |
| Jang, Y | 1 |
| Chung, N | 1 |
| Shim, WH | 1 |
| Cho, SY | 1 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Lim, S | 1 |
| Lee, Y | 1 |
| Sakuma, I | 2 |
| Lee, YH | 1 |
| Han, SH | 1 |
| Shin, EK | 1 |
| Gray, E | 1 |
| Ginty, M | 1 |
| Kemp, K | 1 |
| Scolding, N | 1 |
| Wilkins, A | 1 |
| Bragt, MC | 1 |
| Lalloyer, F | 1 |
| Wouters, K | 2 |
| Baron, M | 1 |
| Caron, S | 1 |
| Vallez, E | 1 |
| Vanhoutte, J | 1 |
| Baugé, E | 2 |
| Shiri-Sverdlov, R | 2 |
| Hofker, M | 1 |
| Staels, B | 4 |
| Tailleux, A | 1 |
| Agouridis, AP | 1 |
| Tsimihodimos, V | 2 |
| Filippatos, TD | 1 |
| Dimitriou, AA | 1 |
| Tellis, CC | 1 |
| Elisaf, MS | 1 |
| Mikhailidis, DP | 3 |
| Tselepis, AD | 2 |
| Rosenson, RS | 1 |
| Fioretto, P | 1 |
| Dodson, PM | 1 |
| Aslibekyan, S | 2 |
| Kabagambe, EK | 1 |
| Straka, RJ | 2 |
| Borecki, IB | 2 |
| Tsai, MY | 1 |
| Hopkins, PN | 2 |
| Shen, J | 1 |
| Lai, CQ | 2 |
| Ordovas, JM | 2 |
| Krishna, SM | 1 |
| Seto, SW | 1 |
| Moxon, JV | 1 |
| Rush, C | 1 |
| Walker, PJ | 1 |
| Norman, PE | 1 |
| Golledge, J | 1 |
| Frazier-Wood, AC | 1 |
| Shirinsky, I | 1 |
| Polovnikova, O | 1 |
| Kalinovskaya, N | 1 |
| Shirinsky, V | 1 |
| Diep, QN | 1 |
| Benkirane, K | 1 |
| Amiri, F | 1 |
| Cohn, JS | 1 |
| Endemann, D | 1 |
| Schiffrin, EL | 1 |
| Kostoula, A | 1 |
| Kakafika, A | 1 |
| Bairaktari, E | 1 |
| Elisaf, M | 2 |
| Kon Koh, K | 1 |
| Yeal Ahn, J | 1 |
| Hwan Han, S | 1 |
| Kyu Jin, D | 1 |
| Sik Kim, H | 1 |
| Cheon Lee, K | 1 |
| Kyun Shin, E | 1 |
| Coban, E | 1 |
| Sari, R | 1 |
| Athyros, VG | 1 |
| Undas, A | 2 |
| Celinska-Löwenhoff, M | 2 |
| Domagala, TB | 1 |
| Iwaniec, T | 1 |
| Dropinski, J | 1 |
| Löwenhoff, T | 1 |
| Szczeklik, A | 2 |
| van Gorp, PJ | 1 |
| Gijbels, MJ | 1 |
| Noel, B | 1 |
| Buffat, L | 1 |
| Maeda, N | 1 |
| van Bilsen, M | 1 |
| Hofker, MH | 1 |
| Okopień, B | 1 |
| Krysiak, R | 1 |
| Herman, ZS | 1 |
| Potaczek, DP | 1 |
| Ichihara, S | 1 |
| Obata, K | 1 |
| Yamada, Y | 1 |
| Nagata, K | 1 |
| Noda, A | 1 |
| Ichihara, G | 1 |
| Yamada, A | 1 |
| Kato, T | 1 |
| Izawa, H | 1 |
| Murohara, T | 1 |
| Yokota, M | 1 |
| Muhlestein, JB | 1 |
| May, HT | 1 |
| Jensen, JR | 1 |
| Horne, BD | 1 |
| Lanman, RB | 1 |
| Lavasani, F | 1 |
| Wolfert, RL | 1 |
| Pearson, RR | 1 |
| Yannicelli, HD | 1 |
| Anderson, JL | 1 |
| Kooistra, T | 1 |
| Verschuren, L | 1 |
| de Vries-van der Weij, J | 1 |
| Koenig, W | 2 |
| Toet, K | 1 |
| Princen, HM | 1 |
| Kleemann, R | 1 |
| Ryan, KE | 1 |
| McCance, DR | 1 |
| Powell, L | 1 |
| McMahon, R | 1 |
| Trimble, ER | 1 |
| Plutzky, J | 1 |
| Wu, J | 1 |
| Sun, M | 1 |
| Lin, JC | 1 |
| He, ZC | 1 |
| Ou, BR | 1 |
| Guo, HS | 1 |
| Hogue, JC | 1 |
| Lamarche, B | 1 |
| Tremblay, AJ | 1 |
| Bergeron, J | 1 |
| Gagné, C | 1 |
| Couture, P | 1 |
| Mansouri, RM | 1 |
| Gervois, P | 1 |
| Wang, B | 1 |
| Habib, A | 1 |
| Merval, R | 1 |
| Lebret, M | 1 |
| Torra, IP | 1 |
| Delerive, P | 1 |
| Fadel, A | 1 |
| Chinetti, G | 1 |
| Fruchart, JC | 1 |
| Najib, J | 1 |
| Maclouf, J | 1 |
| Tedgui, A | 1 |
| Marx, N | 1 |
| Hombach, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate[NCT01426438] | Phase 2 | 99 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Comparison of the Effect of Fenofibrate Versus Curcumin in Type 2 Diabetic Patients Treated With Glimepiride[NCT04528212] | Phase 4 | 60 participants (Actual) | Interventional | 2020-11-01 | Completed | ||
| Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Single Oral Tolvaptan Tablets on Hemodynamic Parameters in Subjects With Heart Failure[NCT00132886] | Phase 2 | 140 participants (Anticipated) | Interventional | 2004-12-31 | Completed | ||
| Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study: A Randomized, Double-Blind Study of Simvastatin, Fenofibrate, and Combined Fenofibrate and Simvastatin in Patients With Controlled Type II Diabetics Without Evidence of Coronary Disease[NCT00309712] | 300 participants | Interventional | 2002-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The absolute change in maximum relative flow mediated dilation (FMD) (%) of the brachial artery from baseline to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | % FMD (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.60 |
| Arm B: Fenofibrate | 0.50 |
Change in C-reactive protein from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | ug/ml (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -0.6 |
| Arm B: Fenofibrate | 0.7 |
Absolute change in total cholesterol from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -9 |
| Arm B: Fenofibrate | -2 |
Change in D-Dimer from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | ug/ml (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.06 |
| Arm B: Fenofibrate | 0.06 |
Change in total HDL particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | nmol/L (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -1.7 |
| Arm B: Fenofibrate | 4.3 |
Absolute change from week 0 to week 24 in insulin resistance as estimated by HOMA-IR (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | HOMA IR Score (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 1.3 |
| Arm B: Fenofibrate | 0.3 |
Change in IL-6 from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.1 |
| Arm B: Fenofibrate | 0.2 |
Change in Large HDL Particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | nmol/L (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 0.9 |
| Arm B: Fenofibrate | -0.3 |
Change in LDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -1 |
| Arm B: Fenofibrate | 7 |
Change in non-HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -17 |
| Arm B: Fenofibrate | -4 |
Change in Small LDL particles from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | nmol/L (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -176 |
| Arm B: Fenofibrate | -119 |
Change in Triglycerides (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | -65 |
| Arm B: Fenofibrate | -54 |
Among men, change in HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 3 |
| Arm B: Fenofibrate | 6.5 |
Among women, change in HDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks
| Intervention | mg/dL (Median) |
|---|---|
| Arm A: Extended-release Niacin With Aspirin | 16 |
| Arm B: Fenofibrate | 8 |
6 reviews available for fenofibrate and Innate Inflammatory Response
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
Anti-inflammatory role of fenofibrate in treating diseases.
Topics: Anti-Inflammatory Agents; Fenofibrate; Humans; Hyperlipidemias; Inflammation; Lipids; PPAR alpha | 2023 |
Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk.
Topics: Adipocytes; Cardiovascular Diseases; Enterocytes; Fenofibrate; Gene Expression Regulation; Humans; H | 2013 |
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dys | 2008 |
Does microvascular disease predict macrovascular events in type 2 diabetes?
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Do | 2011 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
20 trials available for fenofibrate and Innate Inflammatory Response
| Article | Year |
|---|---|
Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
Topics: Adult; Brachial Artery; C-Reactive Protein; Cholesterol, HDL; Delayed-Action Preparations; Dyslipide | 2015 |
Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis.
Topics: Aged; alpha-2-HS-Glycoprotein; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Fenofibrate; H | 2015 |
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.
Topics: Acute-Phase Proteins; Aged; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Artery Disease | 2008 |
[Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
Topics: Aged; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibra | 2009 |
A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA R | 2010 |
Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Female; Fenofibrate; Fibric Ac | 2010 |
Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia.
Topics: Adipokines; Biomarkers; Cross-Over Studies; Female; Fenofibrate; Hemoglobins; Humans; Hypertriglycer | 2011 |
Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Chemokine CCL2; Cholesterol, HDL; Cholesterol, LDL | 2012 |
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Aryldialkylphosphatase; C-Reactive Prot | 2011 |
The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Drug Therapy, Combinati | 2013 |
Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Arteriosclerosis; Biomarkers; C-Reactive Prot | 2004 |
Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis.
Topics: Adult; Biomarkers; C-Reactive Protein; Cardiovascular Physiological Phenomena; Cross-Over Studies; D | 2004 |
The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients.
Topics: Adult; Anti-Inflammatory Agents; C-Reactive Protein; Cholesterol; Female; Fenofibrate; Humans; Hyper | 2004 |
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug | 2005 |
Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antithrombins; beta-Thromboglobulin; Blood Coagu | 2005 |
Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
Topics: Adult; Biomarkers; Blood Glucose; Cytokines; Diet; Female; Fenofibrate; Fibrinogen; Glucose Intolera | 2006 |
Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients.
Topics: Biomarkers; C-Reactive Protein; CD40 Ligand; Female; Fenofibrate; Genetic Predisposition to Disease; | 2006 |
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Di | 2006 |
Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.
Topics: Adult; Arteries; Blood Pressure; Cell Adhesion Molecules; Cytokines; Double-Blind Method; Elasticity | 2007 |
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Female; Fenofibrate; H | 2008 |
53 other studies available for fenofibrate and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.
Topics: Cell Line; COVID-19 Drug Treatment; Cytokines; Fenofibrate; Gene Knockdown Techniques; Glucuronidase | 2022 |
PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome-Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice.
Topics: Animals; Dacryocystitis; Fenofibrate; Fluoresceins; Forkhead Transcription Factors; Inflammation; In | 2022 |
Fenofibrate Ameliorated Systemic and Retinal Inflammation and Modulated Gut Microbiota in High-Fat Diet-Induced Mice.
Topics: Animals; Bacteria; Diet, High-Fat; Fenofibrate; Gastrointestinal Microbiome; Inflammation; Lipopolys | 2022 |
Daily Intake of Smallanthus sonchifolius (Yacon) Roots Reduces the Progression of Non-alcoholic Fatty Liver in Rats Fed a High Fructose Diet.
Topics: Actins; Animals; Asteraceae; Diet; Fenofibrate; Fructose; Inflammation; Insulin; Lipids; Liver; Non- | 2022 |
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells.
Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M | 2022 |
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells.
Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M | 2022 |
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells.
Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M | 2022 |
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells.
Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M | 2022 |
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells.
Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M | 2022 |
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells.
Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M | 2022 |
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells.
Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M | 2022 |
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells.
Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M | 2022 |
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells.
Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M | 2022 |
IL-17A-targeting fenofibrate attenuates inflammation in psoriasis by inducing autophagy.
Topics: Animals; Autophagy; Cytokines; Disease Models, Animal; Fenofibrate; Humans; Inflammation; Interleuki | 2023 |
Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice.
Topics: Animals; Female; Fenofibrate; Humans; Hyperlipidemias; Inflammation; Insulin Resistance; Liver; Mice | 2023 |
Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD).
Topics: Fenofibrate; Humans; Inflammation; Ketoprofen; Lipid Metabolism; Molecular Structure; Non-alcoholic | 2020 |
Dietary fenofibrate attenuated high-fat-diet-induced lipid accumulation and inflammation response partly through regulation of pparα and sirt1 in juvenile black seabream (Acanthopagrus schlegelii).
Topics: Animals; Cytokines; Diet, High-Fat; Down-Regulation; Fenofibrate; Inflammation; Lipid Metabolism; Li | 2020 |
Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy.
Topics: Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytoplasm; | 2020 |
Fenofibrate reverses liver fibrosis in cholestatic mice induced by alpha-naphthylisothiocyanate.
Topics: 1-Naphthylisothiocyanate; Actins; Animals; Apoptosis Regulatory Proteins; Chemical and Drug Induced | 2021 |
An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.
Topics: Biomarkers; C-Reactive Protein; CpG Islands; Cytokines; DNA Methylation; Epigenesis, Genetic; Female | 2017 |
Fenofibrate attenuates fatty acid-induced islet β-cell dysfunction and apoptosis via inhibiting the NF-κB/MIF dependent inflammatory pathway.
Topics: Animals; Apoptosis; B-Lymphocytes; Fatty Acids; Fenofibrate; Hypolipidemic Agents; Inflammation; Int | 2017 |
Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.
Topics: Animals; Chagas Cardiomyopathy; Chagas Disease; Diastole; Fenofibrate; Fibrosis; Humans; Inflammatio | 2017 |
Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation.
Topics: Animals; Capillary Permeability; Caspase 1; Diabetes Mellitus, Experimental; Diabetic Retinopathy; F | 2018 |
Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection.
Topics: Acyl-CoA Dehydrogenase; Animals; Cardiomegaly; Cellular Senescence; Fenofibrate; Gene Expression; Hy | 2018 |
Beneficial effects of fenofibrate in pulmonary hypertension in rats.
Topics: Animals; Female; Fenofibrate; Hypertension, Pulmonary; Inflammation; Monocrotaline; Oxidative Stress | 2018 |
Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; | 2018 |
Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Br | 2019 |
PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
Topics: Adipocytes; Adiponectin; Animals; Chemokine CCL2; Diet, High-Fat; Fenofibrate; Inflammation; Insulin | 2013 |
Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2.
Topics: AMP-Activated Protein Kinases; Animals; Fenofibrate; HEK293 Cells; Humans; Inflammation; Ion Channel | 2013 |
The protective effect of fenofibrate against TNF-α-induced CD40 expression through SIRT1-mediated deacetylation of NF-κB in endothelial cells.
Topics: Acetylation; Antioxidants; Benzamides; CD40 Antigens; Cells, Cultured; Fenofibrate; Human Umbilical | 2014 |
[Anti-fibrosis effects of fenofibrate in mice with hepatic fibrosis].
Topics: Animals; Fenofibrate; Inflammation; Liver Cirrhosis, Experimental; Male; Mice; Mice, Inbred C57BL; P | 2013 |
PPARα Agonist Fenofibrate Ameliorates Learning and Memory Deficits in Rats Following Global Cerebral Ischemia.
Topics: Animals; Brain Ischemia; Cell Death; Cytokines; Fenofibrate; Gene Expression Regulation; Hippocampus | 2015 |
Fenofibrate pre-treatment suppressed inflammation by activating phosphoinositide 3 kinase/protein kinase B (PI3K/Akt) signaling in renal ischemia-reperfusion injury.
Topics: Animals; Base Sequence; DNA Primers; Enzyme Activation; Fenofibrate; Inflammation; Kidney; Male; Mic | 2015 |
PPARα agonists inhibit inflammatory activation of macrophages through upregulation of β-defensin 1.
Topics: Animals; Anti-Inflammatory Agents; beta-Defensins; Cell Line; Culture Media, Conditioned; Dose-Respo | 2015 |
PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Topics: Anilides; Animals; Chemokine CCL2; Cytokines; Disease Models, Animal; Fatty Acids, Nonesterified; Fe | 2015 |
Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis.
Topics: Bronchi; Cells, Cultured; Chemokine CXCL5; Chemokines; Cystic Fibrosis; Dose-Response Relationship, | 2015 |
Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cell Death; Disease Models, Animal; Disease Progression; Fem | 2016 |
Fenofibrate improves high-fat diet-induced and palmitate-induced endoplasmic reticulum stress and inflammation in skeletal muscle.
Topics: Animals; Body Weight; Cell Line; Diet, High-Fat; Endoplasmic Reticulum Stress; Female; Fenofibrate; | 2016 |
A novel PPARα agonist propane-2-sulfonic acid octadec-9-enyl-amide inhibits inflammation in THP-1 cells.
Topics: Anti-Inflammatory Agents; Cell Survival; Chemokines; Fenofibrate; Humans; Inflammation; Lipopolysacc | 2016 |
C/EBP-β Is Differentially Affected by PPARα Agonists Fenofibric Acid and GW7647, But Does Not Change Apolipoprotein A-I Production During ER-Stress and Inflammation.
Topics: Apolipoprotein A-I; Atherosclerosis; Butyrates; Caco-2 Cells; CCAAT-Enhancer-Binding Protein-beta; E | 2017 |
[Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-κB-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease].
Topics: AMP-Activated Protein Kinases; Animals; Cytokines; Diet, High-Fat; Drugs, Chinese Herbal; Fenofibrat | 2017 |
Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study.
Topics: Aged; Blotting, Western; Cell Adhesion; Chronic Disease; Female; Fenofibrate; Heart Failure; Humans; | 2009 |
PPARalpha activator fenofibrate modulates angiotensin II-induced inflammatory responses in vascular smooth muscle cells via the TLR4-dependent signaling pathway.
Topics: Angiotensin II; Animals; Base Sequence; Blotting, Western; Cells, Cultured; DNA Primers; Enzyme-Link | 2009 |
Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy.
Topics: Actins; Animals; Collagen; Diabetic Nephropathies; Fenofibrate; Fibrosis; Hypolipidemic Agents; Infl | 2010 |
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; | 2010 |
Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Topics: Adiponectin; Animals; Blood Glucose; Cnidium; Coumarins; Dietary Fats; Dietary Sucrose; Fatty Liver; | 2011 |
Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function.
Topics: Animals; Catalase; Cell Survival; Cells, Cultured; Cerebral Cortex; Coculture Techniques; Fenofibrat | 2011 |
Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Aorta; Apolipoprotein E2; Atherosclerosis; | 2011 |
A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.
Topics: Adult; C-Reactive Protein; Chemokine CCL2; Female; Fenofibrate; Gene Frequency; Genome-Wide Associat | 2012 |
Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model.
Topics: Angiotensin II; Animals; Aorta; Aorta, Thoracic; Aortic Aneurysm, Abdominal; Apoptosis; Azo Compound | 2012 |
Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.
Topics: Aged; CD36 Antigens; Female; Fenofibrate; Genetic Variation; Genome-Wide Association Study; Humans; | 2012 |
PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
Topics: Angiotensin II; Animals; Blood Pressure; Collagen; Electrocardiography; Fenofibrate; Fibrosis; Heart | 2004 |
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; ATP-Binding Cassette Transporters; Clofibric Acid; Di | 2006 |
Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors.
Topics: Animals; Cytokines; Down-Regulation; Fenofibrate; Glucose; Heart Ventricles; Hypertension; Hypertrop | 2006 |
Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol.
Topics: Animals; Aorta; Aortic Valve; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Cholesterol; Fe | 2006 |
Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Fen | 2007 |
[Impact of fenofibrate on NO and endothelial VCAM-1 expression in hyperlipidemic rats].
Topics: Animals; Atherosclerosis; Cell Adhesion; Endothelium, Vascular; Fenofibrate; Hyperlipidemias; Inflam | 2007 |
Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response.
Topics: Acute-Phase Proteins; Animals; Atherosclerosis; Cell Nucleus; Fenofibrate; Gene Expression Regulatio | 2008 |
Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Fenofibrat | 2008 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cycloox | 1998 |